

Editas Medicine Announces Six Scientific Presentations at the American Society of Gene And Cell Therapy 18th Annual Meeting

May 6, 2015 3:30 AM ET

Cambridge, Mass., May 6, 2015 – Editas Medicine, a leading genome editing company, today announced six abstracts have been accepted for one oral and five poster presentations at the 18th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). The presentations will detail data from research programs across a broad range of disease areas, including cancer, hematologic (blood) and ophthalmic (eye) diseases. The meeting will take place May 13-16 at the Hyatt Regency in New Orleans.

Following is a schedule of Editas' poster and oral presentations:

Cas9-Mediated Genome Editing in Hematopoietic Stem/Progenitor Cells

Authors: Jennifer L. Gori, G. Grant Welstead, McKensie A. Collins, Justin W. Fang, Ari E. Friedland, David Bumcrot

Date/Time: Wednesday, May 13 at 5:15 p.m.

Session Info: Poster Session: Gene Targeting and Gene Correction I

Biophysical Characterization and Direct Delivery of S. Pyogenes Cas9 Ribonucleoprotein Complexes

Authors: William Selleck, Grant Welstead, Justin Fang, McKensie Collins, David Bumcrot, Hari Jayaram

Date/Time: Wednesday, May 13 at 5:15 p.m.

Session Info: Poster Session: Chemical/Molecular Conjugates

Characterization of Cas9-Mediated Genome Editing in Human T Cells

Authors: G. Grant Welstead, Jennifer Gori, Justin Fang, McKensie Collins, Will Selleck, Ari Friedland, Hari Jayaram, David Bumcrot

Date/Time: Thursday, May 14 at 5:30 p.m.

Session Info: Poster Session: Gene Targeting and Gene Correction II

Therapeutic Editing of the HBB Locus Using the Endogenous HBD Locus as a Donor Template

Authors: Cecilia Cotta-Ramusino, Tanushree Phadke, Morgan Maeder, David Bumcrot

Date/Time: Friday, May 15 at 5:30 p.m.

Session Info: Poster Session: Gene Targeting and Gene Correction III

Staphylococcus aureus Cas9: An Alternative Cas9 for Genome Editing Applications

Authors: Ari E. Friedland, Alex Sousa, McKensie Collins, Morgan L. Maeder, Hari Jayaram, Grant G. Welstead, Sebastian Gloskowski, David Bumcrot

Date/Time: Friday, May 15 at 5:30 pm

Session Info: Poster Session: Gene Targeting and Gene Correction III

Therapeutic Correction of an LCA-Causing Splice Defect in the CEP290 Gene by CRISPR/Cas-Mediated Genome Editing

Authors: Morgan L. Maeder, Shen Shen, Erin R. Burnight, Sebastian Gloskowski, Rina Mepani, Ari E. Friedland, Hari Jayaram, Greg Gotta, Budd A. Tucker, David Bumcrot

Date/Time: Saturday, May 16 at 11 a.m.

Session Info: Simultaneous Oral Abstract Sessions: Gene Editing and Gene Regulation III

About Editas Medicine

Editas Medicine is a leading genome editing company and part of a transformational new area of health care – genomic medicine. The company was founded by pioneers and world leaders in genome editing bringing specific expertise in CRISPR/Cas9 and TALENs technologies. The company's mission is to translate its proprietary technology into novel solutions to treat a broad range of genetically driven diseases. For more information, visit www.editasmedicine.com.

###

Media Contact

Dan Budwick

Pure Communications, Inc.

(973) 271-6085

dan@purecommunicationsinc.com